Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan. more
Time Frame | TAK | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.38% | -2.12% | -3% |
1-Month Return | -1.43% | -3.42% | -0.73% |
3-Month Return | -11.49% | -11.13% | 2.87% |
6-Month Return | 3.89% | -5.74% | 7.17% |
1-Year Return | -4.31% | 3.97% | 25.31% |
3-Year Return | -5.76% | 1.05% | 28.38% |
5-Year Return | -34.76% | 34.37% | 81.89% |
10-Year Return | -37.9% | 97.88% | 183.27% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 3.29T | 3.20T | 3.57T | 4.03T | 4.26T | [{"date":"2020-03-31","value":77.19,"profit":true},{"date":"2021-03-31","value":75,"profit":true},{"date":"2022-03-31","value":83.71,"profit":true},{"date":"2023-03-31","value":94.46,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Cost of Revenue | 1.09T | 994.31B | 1.11T | 1.24T | 1.43T | [{"date":"2020-03-31","value":76.13,"profit":true},{"date":"2021-03-31","value":69.46,"profit":true},{"date":"2022-03-31","value":77.32,"profit":true},{"date":"2023-03-31","value":86.91,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Gross Profit | 2.20T | 2.20T | 2.46T | 2.78T | 2.83T | [{"date":"2020-03-31","value":77.73,"profit":true},{"date":"2021-03-31","value":77.8,"profit":true},{"date":"2022-03-31","value":86.93,"profit":true},{"date":"2023-03-31","value":98.28,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Gross Margin | 66.89% | 68.91% | 68.99% | 69.11% | 66.43% | [{"date":"2020-03-31","value":96.78,"profit":true},{"date":"2021-03-31","value":99.71,"profit":true},{"date":"2022-03-31","value":99.82,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":96.12,"profit":true}] |
Operating Expenses | 2.10T | 1.69T | 2.00T | 2.29T | 2.62T | [{"date":"2020-03-31","value":80.25,"profit":true},{"date":"2021-03-31","value":64.71,"profit":true},{"date":"2022-03-31","value":76.44,"profit":true},{"date":"2023-03-31","value":87.58,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Income | 100.41B | 509.27B | 460.84B | 490.50B | 214.07B | [{"date":"2020-03-31","value":19.72,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":90.49,"profit":true},{"date":"2023-03-31","value":96.32,"profit":true},{"date":"2024-03-31","value":42.04,"profit":true}] |
Total Non-Operating Income/Expense | (307.81B) | (286.14B) | (301.18B) | (222.20B) | (301.75B) | [{"date":"2020-03-31","value":-30781100000000,"profit":false},{"date":"2021-03-31","value":-28614400000000,"profit":false},{"date":"2022-03-31","value":-30118000000000,"profit":false},{"date":"2023-03-31","value":-22220000000000,"profit":false},{"date":"2024-03-31","value":-30174700000000,"profit":false}] |
Pre-Tax Income | (60.75B) | 366.24B | 302.57B | 375.09B | 52.79B | [{"date":"2020-03-31","value":-16.2,"profit":false},{"date":"2021-03-31","value":97.64,"profit":true},{"date":"2022-03-31","value":80.67,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":14.07,"profit":true}] |
Income Taxes | (105.04B) | (9.94B) | 72.41B | 58.05B | (91.41B) | [{"date":"2020-03-31","value":-145.08,"profit":false},{"date":"2021-03-31","value":-13.72,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":80.18,"profit":true},{"date":"2024-03-31","value":-126.24,"profit":false}] |
Income After Taxes | 44.29B | 376.17B | 230.17B | 317.04B | 144.20B | [{"date":"2020-03-31","value":11.77,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":61.19,"profit":true},{"date":"2023-03-31","value":84.28,"profit":true},{"date":"2024-03-31","value":38.33,"profit":true}] |
Income From Continuous Operations | 44.29B | 376.17B | 230.17B | 317.04B | 144.20B | [{"date":"2020-03-31","value":11.77,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":61.19,"profit":true},{"date":"2023-03-31","value":84.28,"profit":true},{"date":"2024-03-31","value":38.33,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | 44.24B | 376.00B | 230.06B | 317.02B | 144.07B | [{"date":"2020-03-31","value":11.77,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":61.19,"profit":true},{"date":"2023-03-31","value":84.31,"profit":true},{"date":"2024-03-31","value":38.32,"profit":true}] |
EPS (Diluted) | 3.65 | 28.54 | 0.67 | 0.76 | 18.49 | [{"date":"2020-03-31","value":12.78,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":2.35,"profit":true},{"date":"2023-03-31","value":2.65,"profit":true},{"date":"2024-03-31","value":64.77,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
TAK | |
---|---|
Cash Ratio | 0.38 |
Current Ratio | 1.28 |
Quick Ratio | 0.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TAK | |
---|---|
ROA (LTM) | 2.78% |
ROE (LTM) | 4.15% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TAK | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.53 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.47 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TAK | |
---|---|
Trailing PE | 22.20 |
Forward PE | 36.10 |
P/S (TTM) | 0.01 |
P/B | 0.92 |
Price/FCF | 0 |
EV/R | 2.34 |
EV/Ebitda | 9.11 |
PEG | 1.63 |
Takeda Pharmaceutical Co Ltd ADR (TAK) share price today is $13.1
Yes, Indians can buy shares of Takeda Pharmaceutical Co Ltd ADR (TAK) on Vested. To buy Takeda Pharmaceutical Co Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TAK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Takeda Pharmaceutical Co Ltd ADR (TAK) via the Vested app. You can start investing in Takeda Pharmaceutical Co Ltd ADR (TAK) with a minimum investment of $1.
You can invest in shares of Takeda Pharmaceutical Co Ltd ADR (TAK) via Vested in three simple steps:
The 52-week high price of Takeda Pharmaceutical Co Ltd ADR (TAK) is $14.73. The 52-week low price of Takeda Pharmaceutical Co Ltd ADR (TAK) is $12.29.
The price-to-earnings (P/E) ratio of Takeda Pharmaceutical Co Ltd ADR (TAK) is 22.0508
The price-to-book (P/B) ratio of Takeda Pharmaceutical Co Ltd ADR (TAK) is 0.92
The dividend yield of Takeda Pharmaceutical Co Ltd ADR (TAK) is 5.01%
The market capitalization of Takeda Pharmaceutical Co Ltd ADR (TAK) is $41.95B
The stock symbol (or ticker) of Takeda Pharmaceutical Co Ltd ADR is TAK